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Abstract: 
 
Background: Coaggregating FcεRI with FcγRII receptors holds great potential for treatment of 
IgE-mediated disease by inhibiting FcεRI signaling. We have previously shown that an Fcγ-
Fcε fusion protein, human IgG-IgE Fc fusion protein (GE2), could inhibit FcεRI-
mediated mediator releases in vitro and in vivo. 
Objective: We sought to test whether GE2 was capable of blocking mediator release from FcεRI 
cells sensitized with IgE in vivo or in vitro before exposure to GE2, a critical feature for GE2 to 
be clinically applicable. 
Methods: GE2 was tested for its ability to inhibit Fel d 1–induced mediator release from human 
blood basophils from subjects with cat allergy, human lung-derived mast cells, human 
FcεRIα transgenic mice sensitized with human cat allergic serum, and rhesus monkeys naturally 
allergic to the dust mite Dermatophagoides farinae. 
Results: Basophils from subjects with cat allergy and lung mast cells degranulate when 
challenged with Fel d 1 and anti-IgE, respectively. GE2 itself did not induce mediator release but 
strongly blocked this Fel d 1– and anti-IgE–driven mediator release. GE2 was able to block Fel d 
1–driven passive cutaneous anaphylaxis at skin sites sensitized with human serum from subjects 
with cat allergy in human FcεRIα transgenic mice, but by itself, GE2 did not induce a passive 
cutaneous anaphylaxis reaction. Finally, GE2 markedly inhibited skin test reactivity to D 
farinae in monkeys naturally allergic to this allergen, with complete inhibition being observed at 
125 ng. 
Conclusion: GE2 is able to successfully compete for FcεRs and FcγRs on cells presensitized in 
vitro and in vivo and lead to inhibition of IgE-mediated reactivity through coaggregation of 
FcεRI with FcγRII. 
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Abbreviations 
GE2: Human IgG-IgE Fc fusion protein 
NP: 4-Hydroxy-3-nitrophenylacetyl 
PCA: Passive cutaneous anaphylaxis 
PS: Purified human IgE myeloma protein 
 
The importance of immediate hypersensitive diseases, including those affecting the airways, and 
severe food-induced reactions has become increasingly appreciated in the past decade. 
Traditional immunotherapy with increasing doses of injected allergen has proved effective, 
particularly in upper airway allergy. However, it is very labor intensive, is associated with 
significant adverse events, has shown variable efficacy in lower airway allergic disease (asthma), 
and has proved unsatisfactory for severe food allergy.1 As a result, a variety of new 
immunologically based approaches are under development to treat these conditions. Such 
approaches include anti-IgE therapy,2 antibodies directed to circulating cytokines believed to be 
key in the genesis of these allergic reactions (eg, anti-IL-4, anti-IL-5, and anti-IL-13),3 antibodies 
directed to surface molecules (anti-CD23),4and new forms of immunotherapy, including peptide-
based treatments5and immunotherapy with novel adjuvants (eg, CpG).6 
 
We have developed and tested a novel Fcγ:Fcε human bifunctional Ig fusion protein, human 
IgG-IgE Fc fusion protein (GE2), designed to inhibit basophils, mast cells, and B cells by 
cocrosslinking FcεRI or FcγRII (CD23) with FcγRs (Fig 1).7., 8., 9. However, in those previous 
experiments, we showed that GE2 inhibits mast cell, basophil, and Langerhans-like cell function 
under conditions in which the cells in vitro or in vivo had been artificially sensitized with a 
humanized IgE mAb.7., 8. In the present study we extended the testing of GE2's function to the 
setting of naturally sensitized nonhuman primates, human basophils and mast cells, and 
humanized FcεRI cells in transgenic mice. We now report the results of this series of approaches, 
testing the ability of GE2 to block release from cells that have been sensitized in vivo before GE2 
administration, an ability GE2 must possess if it is to be successful as a therapy in allergic 
subjects. 
 
1. Methods 
 
1.1. Allergy skin test reagents 
 
Dermatophagoides farinae, Dermatophagoides pteronyssinus, and histamine were obtained from 
Allermed Laboratories. For screening skin testing, D farinae and D pteronyssinus were both used 
at 10,000 AU/mL, and histamine was used at 6 mg/mL. Multitest devices were obtained from 
Lincoln Diagnostics. A purified human IgE myeloma protein (PS) was used as an IgE control. 
PS IgE was purified from serum provided as a gift from Dr Ross McIntyre at Dartmouth Medical 
School. 
 
 
Fig 1. Diagram of GE2 fusion protein and the proposed mechanism by which it inhibits FcεRI-mediated 
functions. A, Schematic diagram of GE2 construct. B, Ribbon drawing for the 3-dimensional structure of the 
dimerized GE2. C, Proposed mechanism by which GE2 inhibits FcεRI-mediated degranulation.7 The tetrameric 
αβγ2 FcεRI receptor normally is activated by crosslinking of the IgE-primed FcεRI with multivalent antigen, 
resulting in the activation of Lyn, which in turn phosphorylates ITAMs within the FcεRI and creates docking sites 
for Syk kinase family members that result in signal propagation, which culminates in mast cell activation and 
degranulation. GE2, by binding FcεRI and FcγRIIb as shown, cocrosslinks FcγRIIb with FcεRI, resulting in the 
blocking of IgE-dependent degranulation. This inhibition results from the ITIM activation in FcγRIIb, which leads 
to the interruption of Syk signaling.7 ITAM, Immunoreceptor tyrosine-based activation motif; ITIM, immunoreceptor 
tyrosine-based inhibition motif. 
1.2. Basophil purification 
 
Basophils were obtained from donors who had positive skin test responses for cat dander (Fel d 
1). Donors were taking no medications at the time of donation. Highly purified (>95%) basophils 
were obtained as described previously.10 
 
1.3. Measurement of basophil degranulation 
 
Purified basophils were washed, and GE2 was added (0-10 μg/mL) for 2 hours at 37°C in a 5% 
CO2 incubator. The cells were centrifuged, and the supernatants were removed and stored at 
−70°C to later determine any prerelease of mediators. Cells were washed and activated in 
Dulbecco modified Eagle medium with 1% BSA, 1 mmol/L MgSO4, and 1 mmol/L CaCl2 with 
or without optimal concentrations of Fel d 1 (100 ng/mL, Indoor Biotechnologies). As a control, 
PS IgE was substituted for GE2. After 30 minutes, the supernatant was removed for histamine 
analysis, as described previously.11., 12. 
 
1.4. Lung tissue mast cell release 
 
Fresh human lung tissue chunks of approximately the same size (0.15 g) were washed 4 times 
with RPMI plus 2% FCS/Pen-strep. Tissue was incubated with GE2, PS IgE, or nonspecific 
human IgG for 2 hours in the same media at 37°C. Cells were washed 1 time and challenged for 
45 minutes with anti-human IgE (3 μg/mL) in Tyrodes buffer. The spontaneous release group 
received only medium and no anti-IgE. Tissue was centrifuged at 4°C, and the supernatant was 
removed and stored at −70°C. Fresh medium was added, freeze-thawed 4 times, and centrifuged 
at 5000g to remove tissue debris for the purpose of determining the total amount of β-
hexosamine in the tissue. The supernatants were used to calculate the total levels of β-
hexosamine remaining in the tissue after FcεRI challenge. 
 
1.5. Dust mite allergy testing of rhesus monkeys 
 
Monkeys were sedated with ketamine and then tested on the abdominal skin at 4 sites with a 
MultiTest device. Tests consisted of D farinae and D pteronyssinus at 10,000 AU/mL, histamine 
(6 mg/mL), and saline. Monkeys were scored positive if they showed a wheal equal to or larger 
than 1 cm to D pteronyssinus or D farinae and to histamine. Reactivity in the animals on this 
epicutaneous testing was clearly distinct from that observed in human subjects. The histamine 
and antigen reactions were marked by areas of wheals that were white, with a lack of any 
surrounding erythema. Of 44 animals screened, 5 had negative histamine reactions, and 1 animal 
showed areas of confluent wheals and was judged to be of indeterminate status. Thus of the 38 
animals evaluable, 12 were considered to have positive results to D farinae (a frequency of 32% 
positivity). None of the monkeys showed reactivity to D pteronyssinus. Seven of the monkeys 
with positive results then underwent graded intradermal dose testing on the abdomen with 0.05 
mL of D farinae ranging from 5 to 500 AU/mL. A dose of D farinae causing midlevel reactivity 
was thereby established for each animal (Table I). All procedures involving monkeys were 
performed at the Sabana Seca Station of the Caribbean Primate Research Center, University of 
Puerto Rico. 
 
Table I. Summary of inhibition of skin test results 
 Treatment 
Animal no. GE2, 250 ng PS, 250 ng GE2, 125 ng PS, 125 ng GE2, 62.5 ng PS, 62.5 ng D farinae(dose)∗ Histamine Saline 
 Diameter of bluing reaction (mm) 
R80 0 10 0 16 3 14 12 (50) 14 0 
M221 0 6 0 10 0 13 11 (100) 12 0 
M23A 0 8 2 9 3 12 10 (50) 12 0 
LO6 0 10 0 12 7 13 9 (100) 11 0 
I070 0 8 0 14 16 18 17 (25) 22 0 
Mean (SD), mm 0.0† (0) 8.4 (1.3) 0.4†(0.9) 12.2 (2.8) 5.8‡(5.6) 14.0 (2.1) 10.4 (3.1) 14.2 (4.0) 0 
∗Intradermal challenge dose individualized for animal. 
†P < .0001 compared with their corresponding PS IgE. 
‡P < .01 compared with their corresponding PS IgE. 
 
1.6. Inhibition of D farinae skin reactivity by GE2 in rhesus monkeys 
 
One month after the initial allergy testing, 5 monkeys previously determined to be sensitive to 
dust mite allergen were administered intradermal injections to the abdomen of 0.05 mL of 
increasing concentrations of GE2, or control myeloma human IgE protein PS saline was 
administered at control sites. Five hours later, the animals were administered 5 mL of 0.5% 
Evans Blue dye intravenously, and the abdominal skin test sites were challenged with saline 
(negative control), histamine (positive control), or the dose of D farinae selected from the earlier 
dose-response testing. Sites were photographed 30 minutes later, and the largest diameter of 
bluing was measured. Differences were examined by using the Student t test. 
 
1.7. Passive cutaneous anaphylaxis in human FcεRIα chain transgenic mice 
 
The human FcεRIα chain transgenic mice (kindly provided by Dr Jean-Pierre Kinet, Harvard 
Medical School, Boston, Mass)13., 14. were intradermally injected with 50 μL of 1:5 diluted serum 
from a patient with cat allergy (no. 9632, Plasmalab) to sensitize the skin mast cell sites. Four 
hours later, these same sites were injected with GE2 or control materials. A further 4 hours later, 
the mice were challenged intravenously with 10 μg of purified native Fel d 1 antigen plus 1% 
Evan blue in a volume of 200 μL. Mice were killed 30 minutes after the intravenous challenge. 
 
1.8. Statistical analysis 
 
Data were analyzed by using t tests with the Welch correction to calculate the statistical 
significance between different treatments versus control. P values of .05 or less were considered 
significant. Statistics were performed with GraphPad Prism. 
 
1.9. Protection of research subjects 
 
The testing of rhesus Monkeys was approved by the Institutional Animal Care and Use 
Committee of the University of Puerto Rico and the UCLA Animal Research Committee. The 
murine procedures (passive cutaneous anaphylaxis [PCA]) were approved by the UCLA Animal 
Research Committee. All the studies involved in human mast cells and basophils were approved 
by the Human Studies Committees at Virginia Commonwealth University Health Systems. 
 
2. Results 
 
2.1. GE2 inhibits allergen-induced degranulation from basophils and lung mast cells sensitized in 
vivo 
 
We have previously shown that GE2 inhibited IgE-mediated reactivity in FcεRI-bearing cells 
passively sensitized with 4-hydroxy-3-nitrophenylacetyl (NP)–IgE.7., 8. Here we tested whether 
GE2 could inhibit degranulation of basophils naturally sensitized to Fel d 1 in vivo by using cells 
obtained from donors with cat allergy. Basophil histamine release was inhibited by GE2 in a 
dose-dependent fashion (n = 3, Fig 2), with up to 78% inhibition at 10 μg/mL GE2 (P = .03) 
when cells were challenged with Fel d 1 (100 ng/mL). This inhibition of degranulation did not 
result simply from competition between GE2 and Fel d 1–specific IgE because cells treated with 
nonspecific myeloma IgE (PS) responded to antigen as robustly as cells incubated in medium 
only. These results demonstrate that GE2 can inhibit mediator release from basophils naturally 
sensitized in vivo with Fel d 1–specific IgE. Importantly, GE2 alone, at all concentration tested, 
failed to trigger release, indicating that GE2 itself would not cause degranulation (Fig 2). 
 
 
Fig 2. GE2 inhibits FcεRI-mediated degranulation from basophils obtained from donors with cat allergy. Basophils 
were incubated with or without GE2 or nonspecific control IgE (PS) in Iscove medium at 37°C. The cells were 
incubated with or without 100 ng/mL Fel d 1 for 30 minutes, and mediator release was measured in the supernatants. 
Results are represented as the SEM of 3 experiments from 3 separate donors (± SEM). The asterisk indicates a 
statistically significant P value of .03. 
 
We also examined the ability of GE2 to inhibit anti-IgE–driven mast cell release in human lung 
tissue that had bound IgE in vivo. Anti-IgE–driven mediator release from lung fragments was 
inhibited in a dose-dependent fashion, with almost complete inhibition of the induced release 
occurring with ex vivo treatment of the lung fragments at 50 μg/mL GE2 (P = .04, Fig 3). 
Furthermore the FcεRI dependence of this inhibition was shown because GE2-treated mast cells 
still could be triggered by calcium ionophore, which is known to function through an IgE-
independent pathway (data not shown). 
 
 
Fig 3. GE2 inhibits FcεRI-mediated degranulation from tissue mast cells. Mast cell–containing lung chunks were 
incubated with or without GE2 or nonspecific IgE (PS) or IgG in Iscove medium at 37°C. The tissue chunks were 
incubated with or without 1 μg/mL anti-IgE for 45 minutes, and mediator release was measured in the supernatants. 
Fresh medium was added back to the tissue, which was freeze-thawed 3 times and centrifuged to obtain the total 
amount of histamine. Results are represented as the SEM of 2 experiments (± SEM). The asterisk indicates a 
statistically significant P value of .04. 
 
2.2. GE2 blocks PCA reactivity in human FcεRIα chain transgenic mice presensitized with 
serum from a patient with cat allergy 
 
Although we have previously shown that GE2 is able to compete with coadministered 
monoclonal human IgE to block PCA reactivity in transgenic mice,7 we had not shown whether 
cells presensitized in vivo in transgenic mice could be inhibited by the subsequent administration 
of GE2. To test this, transgenic mice were locally sensitized at individual skin sites with serum 
from a subject highly allergic to cat. Four hours later, GE2 or control material was administered 
to these sites, and after a further 4 hours, the mice were then challenged intravenously with Fel d 
1. 
 
As shown in Fig 4, serum from a patient with cat allergy (no. 9632) was able to produce strong 
PCA reactivity in human FcεRIα transgenic mice on Fel d 1 challenge (Fig 4, A). Treatment of 
the serum from a patient with cat allergy at 56°C for 30 minutes, conditions known to abolish 
IgE binding to FcεRI but not IgG binding to its corresponding receptors, abolished PCA 
reactivity (Fig 4, G), showing that Fel d 1–specific IgE, but not specific IgG, was responsible for 
the PCA reactivity observed. These results indicated that mast cell degranulation was triggered 
by Fel d 1–specific IgE and showed that the human FcεRIα transgenic mice could be used as 
an in vivomodel of human allergic reactivity. PCA reactivity was inhibited in a dose-dependent 
manner by GE2 protein injected 4 hours later, with complete inhibition occurring at 2 μg (Fig 
4, B-D). Reactivity was not blocked with administration of equal amounts of human IgE or 
human IgG with this protocol (data not shown). Purified myeloma IgE (PS IgE), NP-specific 
IgE, and nonallergic human serum (Fig 4, E, F, and H) were not able to function as sensitizing 
reagents in place of the serum from a patient with cat allergy, showing that the PCA reaction was 
mediated by anti-Fel d 1–specific IgE. Additionally, when an intravenous challenge of Fel d 1 
was given immediately after local administration of GE2, there was no local reaction (data not 
shown), demonstrating that GE2 itself is not causing release at the injection sites. 
 
 
Fig 4. GE2 inhibits Fel d 1–specific IgE-mediated mast cell degranulation in vivo. The skin on the back of 
FcεRIα transgenic mice was injected with serum (9632) from a patient with cat allergy (1:5 dilution; a); serum with 
2 μg of GE2 administered 4 hours later (b); serum with 0.2 μg of GE2 (c); serum with 0.02 μg of 
GE2 (d); myeloma IgE (PS, 250 ng; e); NP-specific IgE (250 ng; f); heat-inactivated serum 9632 (56°C for 30 
minutes; g); or nonallergic serum (h). After another 4 hours, the mice were challenged intravenously with 10 μg of 
purified Fel d 1 plus 1% Evans blue dyein 200 μL and killed 30 minutes after challenge. The results are 
representative of 3 experiments with similar results. 
 
2.3. GE2 inhibits naturally occurring skin test reactivity to dust mite in rhesus monkeys 
 
Rhesus monkeys have been reported to express skin test reactivity and serum IgE directed 
toward dust mites.15 We therefore undertook to determine whether GE2 could inhibit skin test 
reactivity in rhesus monkeys. D farinae–reactive monkeys were first screened and identified. D 
farinae–reactive monkeys then underwent graded inhibition testing with GE2 (62.5-250 ng) 
versus purified human IgE myeloma protein (PS) as a control. This control was necessary 
because some inhibition from IgE alone (or the IgE portion of GE2) might be expected. Five 
hours after the test proteins or saline were injected, the sites were then challenged with D 
farinae at a dose individualized for each animal (Table I). GE2 protein effected complete 
inhibition at 250 ng and showed complete inhibition in 4 of 5 animals at 125 ng (Fig 5 and Table 
I). At 62.5 ng, GE2 still exhibited clear inhibition of reactivity compared with saline or control 
(Fig 5). In contrast, PS IgE did not show significant inhibitory effects on skin test reactions in 
any of the doses tested (Fig 5). These results clearly indicate that GE2 protein is able to inhibit 
naturally occurring dust mite allergen–induced allergic skin reactivity in nonhuman primates in a 
dose-dependent fashion. 
 
 
Fig 5. GE2 inhibits dust mite–induced mast cell degranulation in vivo in rhesus monkeys. Sites 3, 5, and 7 were 
injected with 250, 125, and 62.5 ng of GE2, whereas sites 4, 6, and 8 were injected with 250, 125, and 62.5 ng of 
control IgE (PS IgE), respectively. Five hours later, 5 mL of 0.5% Evans blue dye was injected intravenously, and 
the GE2 and PS IgE-injected spots were challenged with a predetermined dose of D farinae allergen. The skin 
reaction was recorded 30 minutes after challenge. A, Skin test results from monkey M23A. B, Skin test results from 
monkey R80. The results are representatives of the 5 monkeys, the results of which are shown in Table I. 
 
3. Discussion 
 
Mast cells and basophils are the primary cell types responsible for initiating the cascade of IgE-
mediated allergic inflammation that results in various signs and symptoms of allergic diseases. 
On allergen-driven crosslinking, IgE bound to its high affinity receptor, FcεRI, expressed on 
mast cells, basophils, or both, triggers degranulation and cytokine production. Recent studies 
have revealed that mast cells also might play a key role in autoimmune disease.16 Thus mast cells 
also appear to be important in inflammatory arthritis,17 experimental allergic 
encephalomyelitis,18 multiple sclerosis,19., 20., 21. and certain type of autoimmune skin disease, 
such as bullous pemphigoid.22 Activation and subsequent degranulation of mast cells through 
FcεRI crosslinking (in both human subjects and mice), FcγRIII (in mice), or both are thought to 
be the critical steps for these processes.16 Therefore inhibition of mast cell activation, 
degranulation, and cytokine production provides for a potential therapeutic target for the 
prevention, treatment, or both of allergic disorders, as well as autoimmune diseases. 
 
The previously constructed GE2 was shown to inhibit FcεRI-mediated functions of basophils, 
mast cells, and Langerhans-like dendritic cells in vitro and in vivo.7., 8. This activity was shown to 
be related to the ability of GE2 to coaggregate FcεRs and FcγRs (Fig 1). However, in those 
experiments the purified humanized IgE mAb (anti-NIP or anti-dansyl IgE) was used in the 
experiments to trigger IgE-dependent degranulation or mediator release. Whether GE2 would be 
able to block (1) human naturally produced allergen-specific IgE-derived reactivity and (2) 
reactivity in which the target cells had been presensitized by allergen-specific IgE in 
vivo remained to be tested. These questions were necessary to test the potential clinical relevance 
of GE2 for the inhibition of FcεRI-mediated reactivity signaling. 
 
In this report we approached the ability of GE2 to block already sensitized cells by using a 
variety of experimental systems. The mediator release of the Fel d 1–specific IgE-presensitized 
basophils from subjects highly allergic to cats and the lung mast cells loaded with IgE in 
vivo was significantly inhibited by GE2. GE2 also exhibited strong inhibitory effects on sera 
from sensitized patients with cat allergy, naturally occurring cat allergen Fel d 1–induced allergic 
degranulation of mast cells in FcεRIα transgenic mice, and on naturally occurring dust mite 
allergen D farinae–mediated allergic skin reactions in rhesus monkeys. These results, obtained 
from the more clinically relevant settings in contrast to the use of artificial human IgE that was 
used in the previous experiments,7., 8. further validate the potential of GE2 as a therapeutic 
approach to treat IgE-mediated allergic diseases. Given that GE2 is able to inhibit degranulation 
of FcεRI-bearing cells triggered by NP-, Dansyl-, Fel d 1–, and dust mite-specific IgE in various 
experimental systems (and this report),7., 8. it is evident that GE2 functions to broadly inhibit 
degranulation through a nonallergen-specific fashion. Such a feature provides the basis for GE2 
as a general inhibitor for IgE-mediated, but not limited to allergen-specific, allergic reactions. 
 
The allergic reaction to dust mite allergen D farinae in monkeys provided us a more clinically 
relevant naturally occurring experimental system to test GE2's efficacy to inhibit an allergen-
specific allergic response. Allergic skin reactions were strongly inhibited by GE2 but not by 
equal amounts of nonspecific IgE, indicating that the inhibitory effects of GE2 were due to the 
specific property of GE2 and not simply an Fcε effect. Clearly, mere competition for occupancy 
of FcεRI by Fcε was not sufficient to inhibit the allergen-induced skin reaction. This supports our 
molecular studies showing that GE2 exerts its strong inhibitory effects through negative 
signaling of FcεRI-FcγRIIb coaggregation.7 This in vivo result is consistent with our previous in 
vitro observation that GE2 was able to prevent the phenotypic change of degranulation of mast 
cells (Kepley at al, unpublished observation). 
 
Taken together, the data demonstrate that GE2 functions in a nonallergen-specific manner to 
inhibit IgE-dependent allergic reactions in vitro and in vivo, including artificially and naturally 
sensitized basophils and mast cells, including in nonhuman primates and transgenic mice 
expressing humanized FcεRI cells. In addition, other studies have shown that GE2 inhibits B-cell 
IgE production and human Langerhans cell proallergic activity.8., 9. It should be noted that all the 
tests conducted thus for were either experiments in vitro or local tests in vivo. The effects of GE2 
on inhibiting systemic allergic responses, such as asthma, should be tested when an appropriate 
animal model is available. Overall, these studies provide strong support for the next step of 
initiating human clinical trails with the GE2 therapeutic platform. 
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